Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

94.29
Delayed Data
As of Sep 30
 +2.00 / +2.17%
Today’s Change
55.00
Today|||52-Week Range
131.33
-13.06%
Year-to-Date
ARIAD (ARIA) Leukemia Drug Iclusig Gets Approval in Japan
Sep 30 / Zacks.com - Paid Partner Content
3 Buyout Targets That Could Get Snatched Up
Sep 21 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close92.29
Today’s open92.71
Day’s range90.57 - 94.66
Volume1,707,564
Average volume (3 months)1,182,904
Market cap$17.4B
Dividend yield--
Data as of 4:00pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+476.82%
Earnings growth (next 5 years)+170.10%
Revenue growth (last year)+47.36%
P/E ratio248.1
Price/Sales26.95
Price/Book100.65

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...-0.26-0.28%
MYLMylan NV-0.35-0.91%
VRTXVertex Pharmaceutica...+2.21+2.60%
----
Data as of 3:59pm ET, 09/30/2016

Financials

Next reporting dateOctober 27, 2016
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts

Search for Jobs